EUVIMEDEUVIMED entdecken
Crossref

The Use of Anemia Control Model Is Associated with Improved Hemoglobin Target Achievement, Lower Rates of Inappropriate Erythropoietin Stimulating Agents, and Severe Anemia among Dialysis Patients

Mario Garbelli, Francesco Bellocchio, Maria Eva Baro Salvador, Milena Chermisi, Abraham Rincon Bello, Isabel Berdud Godoy, Sofia Ortego Perez, Kateryna Shkolenko, Alicia Sobrino Perez, Diana Samaniego Toro, Christian Apel, Jovana Petrovic und 4 weitere

Blood Purification · 2024 · 53 (5) · 405-417

DOI: 10.1159/000536181 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood Purification, online erschienen am 21.02.2024. Verfasst von Mario Garbelli und 15 weiteren Autor:innen. Beteiligte Einrichtung: Global Medical Office - Clinical Advanced Analytics - Data Science - EMEA, APAC, LATAM region, Fresenius Medical Care Italia spa, Vaiano Cremasco, It…. Hauptthemen laut MEDLINE: Hematinics, Anemia, Erythropoietin. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The Anemia Control Model (ACM) is a certified medical device suggesting the optimal ESA and iron dosage for patients on hemodialysis. We sought to assess the effectiveness and safety of ACM in a large cohort of hemodialysis patients.

Methods

This is a retrospective study of dialysis patients treated in NephroCare centers between June 1, 2013 and December 31, 2019. We compared patients treated according to ACM suggestions and patients treated in clinics where ACM was not activated. We stratified patients belonging to the reference group by historical target achievement rates in their referral centers (tier 1: <70%; tier 2: 70–80%; tier 3: >80%). Groups were matched by propensity score.

Results

After matching, we obtained four groups with 85,512 patient-months each. ACM had 18% higher target achievement rate, 63% smaller inappropriate ESA administration rate, and 59% smaller severe anemia risk compared to Tier 1 centers (all p < 0.01). The corresponding risk ratios for ACM compared to Tier 2 centers were 1.08 (95% CI: 1.08–1.09), 0.49 (95% CI: 0.47–0.51), and 0.64 (95% CI: 0.61–0.68); for ACM compared to Tier 3 centers, 1.01 (95% CI: 1.01–1.02), 0.66 (95% CI: 0.63–0.69), and 0.94 (95% CI: 0.88–1.00), respectively. ACM was associated with statistically significant reductions in ESA dose administration.

Conclusion

ACM was associated with increased hemoglobin target achievement rate, decreased inappropriate ESA usage and a decreased incidence of severe anemia among patients treated according to ACM suggestion.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HematinicsAnemiaErythropoietinHumansRenal DialysisRetrospective StudiesHemoglobins

Stichwörter der Autor:innen

Anemia managementArtificial intelligenceEnd stage kidney diseaseErythropoietin stimulating agentsHemoglobinMedical deviceSecondary anemia

Substanzen

HematinicsErythropoietinHemoglobins

Autor:innen und Institutionen

  • Global Medical Office - Clinical Advanced Analytics - Data Science - EMEA, APAC, LATAM region, Fresenius Medical Care Italia spa, Vaiano Cremasco, Italy, mario.garbelli@fmc-ag.com.
  • Global Medical Office - Clinical Advanced Analytics - Data Science - EMEA, APAC, LATAM region, Fresenius Medical Care Italia spa, Vaiano Cremasco, Italy.
  • Country Medical Office - NephroCare Spain, Fresenius Medical Care, Madrid, Spain.
  • Health Economics and Market Access, Fresenius Medical Care, Bad Homburg, Germany.
  • Global Medical Office - Clinical and Therapeutic Governance EMEA, Fresenius Medical Care, Bad Homburg, Germany.
  • Global Digital Transformation and Innovation, Clinical Digital Center of Excellence, Fresenius Medical Care, Vaiano Cremasco, Italy.

Zitieren

APA

Garbelli, M., Bellocchio, F., Baro Salvador, M. E., Chermisi, M., Rincon Bello, A., Godoy, I. B., Perez, S. O., Shkolenko, K., Perez, A. S., Toro, D. S., Apel, C., Petrovic, J., Stuard, S., Barbieri, C., Mari, F., & Neri, L. (2024). The Use of Anemia Control Model Is Associated with Improved Hemoglobin Target Achievement, Lower Rates of Inappropriate Erythropoietin Stimulating Agents, and Severe Anemia among Dialysis Patients. Blood Purification, 53(5), 405-417. https://doi.org/10.1159/000536181

Vancouver

Garbelli M, Bellocchio F, Baro Salvador ME, Chermisi M, Rincon Bello A, Godoy IB, et al. The Use of Anemia Control Model Is Associated with Improved Hemoglobin Target Achievement, Lower Rates of Inappropriate Erythropoietin Stimulating Agents, and Severe Anemia among Dialysis Patients. Blood Purification. 2024;53(5):405-417. doi:10.1159/000536181

BibTeX
@article{Garbelli2024,
  author = {Garbelli, Mario and Bellocchio, Francesco and Baro Salvador, Maria Eva and Chermisi, Milena and Rincon Bello, Abraham and Godoy, Isabel Berdud and Perez, Sofia Ortego and Shkolenko, Kateryna and Perez, Alicia Sobrino and Toro, Diana Samaniego and Apel, Christian and Petrovic, Jovana and Stuard, Stefano and Barbieri, Carlo and Mari, Flavio and Neri, Luca},
  title = {The Use of Anemia Control Model Is Associated with Improved Hemoglobin Target Achievement, Lower Rates of Inappropriate Erythropoietin Stimulating Agents, and Severe Anemia among Dialysis Patients},
  journal = {Blood Purification},
  year = {2024},
  volume = {53},
  number = {5},
  pages = {405--417},
  doi = {10.1159/000536181}
}
Kostenlos starten →